These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2094334)

  • 41. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator.
    Matsui D; Hermann C; Klein J; Berkovitch M; Olivieri N; Koren G
    J Clin Pharmacol; 1994 Sep; 34(9):944-9. PubMed ID: 7983239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experience with the oral iron chelator deferiprone in transfusion-dependent children.
    Lucas GN; Perera BJ; Fonseka EA; De Silva DD; Fernandopulle M; Karunatilaka DH; Weerasinghe I
    Ceylon Med J; 2002 Dec; 47(4):119-21. PubMed ID: 12661341
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of an HPLC method for measuring orally administered 1-substituted 2-alkyl-3-hydroxypyrid-4-one iron chelators in biological fluids.
    Goddard JG; Kontoghiorghes GJ
    Clin Chem; 1990 Jan; 36(1):5-8. PubMed ID: 2297936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iron chelation therapy.
    Hoffbrand AV; Wonke B
    J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.
    Mehta J; Chablani A; Reporter R; Singhal S; Mehta BC
    J Assoc Physicians India; 1993 Jun; 41(6):339-41. PubMed ID: 8005967
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
    Sheikh-Taha M; Koussa S; Inati A; Taher A
    Hemoglobin; 2007; 31(4):499-501. PubMed ID: 17994386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deferiprone: New insight.
    Piga A; Roggero S; Vinciguerra T; Sacchetti L; Gallo V; Longo F
    Ann N Y Acad Sci; 2005; 1054():169-74. PubMed ID: 16339662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Goddard JG; Bartlett AN; Sheppard L
    Clin Pharmacol Ther; 1990 Sep; 48(3):255-61. PubMed ID: 2401124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.
    Hoffbrand AV; Bartlett AN; Veys PA; O'Connor NT; Kontoghiorghes GJ
    Lancet; 1989 Aug; 2(8660):457. PubMed ID: 2569644
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
    Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
    Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
    Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
    Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF; Peng CT; Wu KH; Tsai CH
    Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deferiprone for the treatment of transfusional iron overload in thalassemia.
    Belmont A; Kwiatkowski JL
    Expert Rev Hematol; 2017 Jun; 10(6):493-503. PubMed ID: 28448199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Arthropathy in thalassaemia patients receiving deferiprone.
    Berkovitch M; Laxer RM; Inman R; Koren G; Pritzker KP; Fritzler MJ; Olivieri NF
    Lancet; 1994 Jun; 343(8911):1471-2. PubMed ID: 7911181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
    Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.